An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors

What is the purpose of this trial?

This study will evaluate the safety, tolerability and pharmacokinetic variability of atezolizumab, in combination with bevacizumab and/or Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) at the dose level and schedule indicated for hepatocellular carcinoma (HCC) (Arm A) and gastric cancer (Arm B), and in combination with nab-paclitaxel and gemcitabine at the dose level and schedule indicated for metastatic pancreatic cancer (Arm C).


Participation Guidelines

Ages: 18 years and older

Gender: Both


Hoffman-La Roche

Dates: 06/28/2016 - 05/31/2019

Last Updated: 03/02/2017

Study HIC#: 1602017234

Get Involved

For more information about this study, contact:
Kamil Sadowski
+1 203-785-6666
kamil.sadowski@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Stacey M Stein

Principal Investigator

Sub-Investigators